The functional role of natural killer cells early in clinical sepsis

APMIS

Volumn 121, Issue 4, 2013, Pages 329-336

  Giannikopoulos, George ^a   Antonopoulou, Anastasia ^b   Kalpakou, Georgia ^c   Makaritsis, Konstantinos ^d   Panou, Charalambos ^e   Papadomichelakis, Evangelos ^b   Sinapidis, Dimitrios ^b   Theodotou, Anna ^f   Tzagkaraki, Aikaterini ^g   Giamarellos Bourboulis, Evangelos J ^b  

^a Chios General Hospital   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Zakynthos General Hospital   (Greece)

^d GENERAL HOSPITAL OF LARISSA   (Greece)

^e General Hospital of Lamia   (Greece)

^f Karditsa General Hospital   (Greece)

^g SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Interferon gamma; Interleukin 23; Natural killer cells; Sepsis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

AGED; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

ADULT; AGED; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-23; INTERLEUKIN-6; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS;

EID: 84875666889     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12002     Document Type: Article

References (23)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2003;34:1084-93.
3. Ranieri M, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
4. Rittisch D, Flier MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Immunol 2008;8:776-86.
5. Giamarellos-Bourboulis EJ, van de Veerdonk FL, Mouktaroudi M, Raftogiannis M, Antonopoulou A, et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit Care 2011;15:R27.
6. Souza-Foncesa-Guimaraes F, Abid-Conquy M, Cavaillon JM. NK cells in anti-bacterial innate immunity: angels of devils? Mol Med 2012;18:270-85.
7. Andaluz-Ojeda D, Iglesias V, Bobillo F, Almansa R, Rico L, Gandía F, et al. Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care 2011;15:R243.
8. Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, et al. Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care 2006;10:R166-73.
9. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004;363:600-7.
10. Kollef MH. Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Med 2003;29:147-9.
11. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001;120:955-70.
12. Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB. Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med 1997;15:148-51.
13. Calandra T, Cohen J. The International Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med 2005;33:1639-48.
14. Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international definition sepsis conference. Crit Care Med 2003;31:1250-6.
15. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, et al. Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect 2011;77:58-63.
16. Balzan S, De Almedia Quadros C, de Cleva R, Zilberstein B, Cecconello I. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol 2006;22:464-71.
17. Chiche L, Forel JM, Thomas G, Farnarier C, Vely F, Bléry M, et al. The role of natural killer cells in sepsis. J Biomed Biotechnol 2011;2011:986491.
18. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J Immunol 2008;180:6334-45.
19. Romero CR, Herzig DS, Etogo A, Nunez J, Mahmoudizad R, Fang G, et al. The role of interferon-γ in the pathogenesis of intra-abdominal sepsis. J Leukoc Biol 2010;88:725-35.
20. Anthony DA, Andrews DM, Chow M, Watt SV, House C, Akira S, et al. A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J Immunol 2010;185:1794-803.
21. Mylona V, Koussoulas V, Tzivras D, Makrygiannis E, Georgopoulou P, Koratzanis G, et al. Changes in adaptive and innate immunity in patients with acute pancreatitis and systemic inflammatory response syndrome. Pancreatology 2011;11:475-81.
22. McCall CE, Yoza BK. Gene silencing in severe systemic inflammation. Am J Resp Crit Care Med 2007;175:763-7.
23. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006;10:233.